CA2870626C - 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a beta-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof - Google Patents

2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a beta-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof Download PDF

Info

Publication number
CA2870626C
CA2870626C CA2870626A CA2870626A CA2870626C CA 2870626 C CA2870626 C CA 2870626C CA 2870626 A CA2870626 A CA 2870626A CA 2870626 A CA2870626 A CA 2870626A CA 2870626 C CA2870626 C CA 2870626C
Authority
CA
Canada
Prior art keywords
beta
cerebral
abcc1
transporter
proband
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2870626A
Other languages
English (en)
French (fr)
Other versions
CA2870626A1 (en
Inventor
Jens Pahnke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immungenetics AG
Original Assignee
Immungenetics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immungenetics AG filed Critical Immungenetics AG
Publication of CA2870626A1 publication Critical patent/CA2870626A1/en
Application granted granted Critical
Publication of CA2870626C publication Critical patent/CA2870626C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
CA2870626A 2010-09-07 2011-08-30 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a beta-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof Active CA2870626C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102010044561 2010-09-07
DE102010044561.4 2010-09-07
CA2811454A CA2811454C (en) 2010-09-07 2011-08-30 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a b-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2811454A Division CA2811454C (en) 2010-09-07 2011-08-30 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a b-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof

Publications (2)

Publication Number Publication Date
CA2870626A1 CA2870626A1 (en) 2012-03-15
CA2870626C true CA2870626C (en) 2018-08-14

Family

ID=44645670

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2870626A Active CA2870626C (en) 2010-09-07 2011-08-30 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a beta-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof
CA2811454A Active CA2811454C (en) 2010-09-07 2011-08-30 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a b-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2811454A Active CA2811454C (en) 2010-09-07 2011-08-30 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a b-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof

Country Status (13)

Country Link
US (3) US20130184268A1 (enExample)
EP (3) EP2693216B1 (enExample)
JP (2) JP6084924B2 (enExample)
CN (2) CN106243060A (enExample)
BR (1) BR112013005472A2 (enExample)
CA (2) CA2870626C (enExample)
DE (2) DE102010062810B4 (enExample)
DK (2) DK2614060T3 (enExample)
ES (2) ES2605705T3 (enExample)
MX (1) MX357521B (enExample)
PL (2) PL2614060T3 (enExample)
RU (2) RU2016118021A (enExample)
WO (1) WO2012031941A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
BR112021000802A2 (pt) 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
WO2021188457A1 (en) * 2020-03-16 2021-09-23 Doublerainbow Biosciences Inc. Etoposide glycosides, methods of making, and uses thereof as an anti-cancer drug
JP7897954B2 (ja) * 2022-01-04 2026-07-30 イムヌジェネティクス アーゲー アルツハイマー型認知症の処置又は予防における使用のための特定の投与量のフェノチアジン化合物
EP4605754A1 (en) * 2022-10-18 2025-08-27 Immungenetics AG Identifying a subject suffering from alzheimer's dementia or being at risk of developing alzheimer's dementia

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH365379A (de) * 1956-04-18 1962-11-15 Sandoz Ag Verfahren zur Herstellung von neuen, in 3-Stellung mit einer einwertigen Schwefelfunktion substituierten Phenothiazinen
BE568701A (enExample) * 1957-06-18
US3621097A (en) * 1970-03-30 1971-11-16 Jan Marcel Didier Aron Samuel Method and compositions for treatment of mental illness
US4471116A (en) * 1982-07-28 1984-09-11 Hoffmann-La Roche Inc. Substituted (10H-phenothiazin-10-L)-propyl-1-piperazines
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
WO1996004915A1 (en) * 1994-08-08 1996-02-22 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) * 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
EP1470818B1 (en) * 2003-04-25 2006-07-26 Neuro3D Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns
DE102005014142B4 (de) * 2005-03-23 2006-11-09 Hennig Arzneimittel Gmbh & Co. Kg Pelletförmige Retardzubereitung gegen Schwindel
WO2007062862A2 (en) * 2005-12-02 2007-06-07 Ludwig Maximilians Universität München Use of calmodulin inhibitors for the treatment of neurodegenerative disorders
MY162313A (en) * 2006-07-11 2017-05-31 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
JP5244810B2 (ja) * 2006-11-10 2013-07-24 カラ セラピューティクス インコーポレイテッド 合成ペプチドアミド
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
TW200848063A (en) * 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
MX2010011880A (es) * 2008-04-29 2011-05-25 Pharnext Nuevos enfoques terapeuticos para tratar la enfermedad del alzheimer y trastornos relacionados mediante una modulacion de la respuesta de estres celular.
NZ589307A (en) * 2008-04-29 2012-04-27 Pharnext Compositions comprising baclogen or terbinafine for treating alzheimer disease and related disorders through a modulation of angiogenesis
WO2009133128A1 (en) * 2008-04-29 2009-11-05 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
US9399032B2 (en) * 2009-05-14 2016-07-26 The General Hospital Corporation Methods and compositions for treating degenerative and ischemic disorders

Also Published As

Publication number Publication date
US9370523B2 (en) 2016-06-21
CA2811454A1 (en) 2012-03-15
RU2016118021A3 (enExample) 2020-02-26
RU2013110018A (ru) 2014-10-20
US20150024418A1 (en) 2015-01-22
DK2614060T3 (da) 2017-01-02
ES2701453T3 (es) 2019-02-22
EP3097914A2 (de) 2016-11-30
MX357521B (es) 2018-07-12
CA2811454C (en) 2017-03-28
JP2013537881A (ja) 2013-10-07
US20130184268A1 (en) 2013-07-18
EP2614060B1 (de) 2016-08-31
US20150374711A1 (en) 2015-12-31
CN103237802B (zh) 2017-06-09
MX2013002612A (es) 2013-08-01
RU2016118021A (ru) 2018-11-01
EP2693216B1 (de) 2018-09-12
BR112013005472A2 (pt) 2020-11-10
CA2870626A1 (en) 2012-03-15
CN106243060A (zh) 2016-12-21
JP6084924B2 (ja) 2017-02-22
JP6426663B2 (ja) 2018-11-21
RU2587154C2 (ru) 2016-06-20
PL2693216T3 (pl) 2019-04-30
ES2605705T3 (es) 2017-03-15
DE102010062810B4 (de) 2014-03-13
JP2017019776A (ja) 2017-01-26
PL2614060T3 (pl) 2017-05-31
EP2693216A1 (de) 2014-02-05
WO2012031941A2 (de) 2012-03-15
EP2614060A2 (de) 2013-07-17
EP3097914A3 (de) 2016-12-28
DE102010062810A1 (de) 2012-03-08
WO2012031941A3 (de) 2012-09-20
CN103237802A (zh) 2013-08-07
DK2693216T3 (en) 2019-01-14
DE102011053114A1 (de) 2012-03-08

Similar Documents

Publication Publication Date Title
Peters et al. BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology
US9370523B2 (en) Method for diagnosing or prediagnosing a beta-amyloidopathy or an alpha-synucleopathy
JP7419486B2 (ja) τリン酸化を阻害する方法
Krohn et al. Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice
US8741883B2 (en) Compounds and methods for the diagnosis and treatment of amyloid associated diseases
JP6566867B2 (ja) 生きている患者でのアルツハイマー病アッセイ
EP2853293B1 (en) Thioninium compounds and their use
CN101460157A (zh) 蛋白聚集抑制剂
Zouambia et al. Proteasome subunit proteins and neuropathology in tauopathies and synucleinopathies: Consequences for proteomic analyses
US20240398783A1 (en) Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereof
EP4590666A1 (en) Thiazole derivatives as tau aggregation inhibitors
JP2008530999A (ja) ミクログリア促進アミロイド形成のアッセイ
HK1208000B (en) Thioninium compounds and their use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160823

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - SMALL

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240826

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240826

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240826

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - SMALL

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250818

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250903